Boston Scientific Acquires EMcision Ltd.

EMcision Ltd., a privately-held company headquartered in London, UK that develops and commercializes proprietary medical devices, announced that it and its subsidiaries have been acquired by Boston Scientific, the world’s premier endoscopic devices company.
 
Founded by internationally renowned surgeon and inventor, Prof. Nagy Habib, EMcision develops innovative devices including the Habib 4X, the Habib EndoHPB and the Habib EUS RFA. Those products have benefited close to 100,000 patients suffering from cancers of the liver, pancreas, and bile ducts.
 
EMcision’s flagship product, the Habib EndoHPB, was the world’s first endoscopic device for tumor ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma.
 
“Recently, two randomized clinical trials showed independently a statistically significant survival advantage for patients treated with the Habib EndoHPB,” said Prof. Nagy Habib, EMcision’s Chairman and founder. “This new treatment has empowered endoscopists with a very useful device for management of these unfortunate patients with advanced cancer.”
 
EMcision devices are sold in 38 countries around the world and used by surgeons and endoscopists in most of the top US cancer centers such as MD Anderson, Memorial Sloan Kettering, Mayo Clinic, Cleveland Clinic, Johns Hopkins, Massachusetts General, and Stanford.

“By partnering with Boston Scientific, we will continue delivering on our mission of improving the quality of life of cancer patients on a much larger scale. Boston Scientific has the resources and the know-how to further improve our technology, expand clinical indications and make it available to many more patients,” said Cherif Habib, EMcision’s outgoing CEO.